Friday, April 26, 2019
Home Health Cancer-causing chemicals spark THIRD recall of blood pressure

Cancer-causing chemicals spark THIRD recall of blood pressure

THOUSANDS of heart patients are diagnosed with cancer.

Pharmacies across the country are advised to recall batches of the drug irbesartan.

  Three batches of heart have been recalled today, amid fears of contamination with cancer-causing chemicals
Three batches of heart have been recalled today, amid fears of contamination with cancer-causing chemicals

It's the third recall of its kind since the start of the year.

The Medicines and Healthcare products regulatory agency (MHRA) said there were concerns that could contain cancer-causing chemicals.

Accord and Dexcel were recalled, and more batches from Macleods Pharma UK were affected.

Today's recall affects batches made by Actavis Pharma UK Limited, the MHRA said.

Do not stop taking drugs, but see your GP – patients told

The advice to patients is not to stop their medication.

But people are being urged to look at their GPs.

There is no evidence that the MHRA stressed.

Dr Sam Atkinson MHRA's Director of Inspection, Enforcement and Standards Division said: "Patient safety is our top priority and we want to take any necessary steps to protect public health.

"Today's Irbesartan recall shows we are continuing to investigate potential contamination of sartan containing medicines.

"Because of the risk associated with sudden stopping high blood pressure medication, continue to take your medicines as prescribed by your doctor."

"Please speak to your doctor or pharmacist if you have any concerns about your medicine."

Drugs that treat high blood pressure, heart attack and heart failure

Sartans are a class of medications used to treat high blood pressure, heart attack and heart failure.

It follows an earlier recall of heart medication Dexcel and Actavis in July and Mylan and Teva in November, which contained the same chemical.

Sartan drug, valsartan, produced at a facility in China.

Drugs are being recalled across Europe, as are known anxiety impurities (N-nitrosodimethylamine and N-nitrosodiethylamine), which could be carcinogenic as well as a result of a change in the manufacturing process.

"Currently there is no evidence that NDA or NDEA has any harm to patients," Dr Atkinson added.

The European Medicines Agency and other EU regulators are working together to investigate how widespread the problem is and the potential impact for patients.

THREE BATCHES RECALLED TODAY

THESE are the three batches of Actavis Pharma UK Ltd.

1. Irbesartan 300mg film-coated tablets, PL30306 / 0108

Batch number – 191018

Expiry date – 05/2020

Pack size – 1×28

First distributed – Nov 30, 2018

2. Irbesartan 300mg film-coated tablets, PL30306 / 0108

Batch number – 191118

Expiry date – 05/2020

Pack size – 1×28

First distributed – Dec 20, 2018

3. Irbesartan / Hydrochlorothiazide 300 / 25mg film-coated tablets, PL 30306/0267

Batch number – 263918

Expiry date – 06/2020

Pack size – 1×28

First distributed – Nov 21, 2018

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Must Read

Meet the first round of the draft with expectations

NASHVILLE - Little space for surprises in the opening round of the 2019 Draft: Kyler Murray was chosen by the Arizona Cardinals as the...

Petfanks and Teether steal $ 851 million – Arab Folio

In an important and dangerous news in the digital currency market, the New York State Prosecutor investigates the case involving both Bitfinex and Tether,...